Insulet (NSDQ:PODD) topped estimates on Wall Street yesterday with its first-quarter results, topping analysts’ sales expectations by $1.9 million.
The Billerica, Mass.-based company reeled in its losses, posting a net loss of -$6.6 million, or -11¢ per share, on sales of $123.6 million for the 3 months ended March 31, for bottom-line growth of 34.2% on sales growth of 21.5% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulet sales grow 22% in Q1 appeared first on MassDevice.
from MassDevice https://ift.tt/2rirRjs
Cap comentari:
Publica un comentari a l'entrada